Rocket Lab's Two-Track Reality: A Contract Machine Grinding Against a Halved Share Price
Published on 08/07/2026 at 13:32 | Redaktion boerse-global.de
There is a peculiar disconnect playing out in Rocket Lab's stock right now. The company is stacking up contract wins, launching missions at a steady clip, and closing in on the biggest acquisition in its history — yet the share price sits roughly 50 percent below its 52-week peak. On Thursday, the stock closed at EUR 65.90, up 1.54 percent, extending a seven-session run that has added 16.84 percent. Even after that bounce, the equity remains about 50.75 percent off its high of EUR 133.80. The gap between operational momentum and market valuation has rarely been wider.
A Pipeline That Keeps Delivering
The recent flow of announcements reads like a highlight reel for the company's growth thesis. Early August brought a USD 397 million contract from the US Space Force under the Space-Based Airborne Moving Target Indicator program. Rocket Lab will develop, launch, and operate the so-called "flatellites" — with launches slated for the Neutron rocket, a vehicle that has yet to make its maiden flight. Just days earlier, on July 27, the company announced what it called its largest launch contract ever: USD 266 million for suborbital launches tied to missile defense. Sandwiched between those milestones, Japanese customer iQPS booked a third batch of dedicated Electron missions, announced July 30, extending the relationship through 2030.
The launch cadence backs up the backlog. Thursday marked the 13th Electron mission of the year and the eighth dedicated flight for iQPS — though it came about five weeks later than originally planned, with the next iQPS launch tentatively set for late August from New Zealand. At the end of the first quarter, the order book stood at USD 2.2 billion, with revenue growth of 63.5 percent year over year. For the second quarter, the consensus calls for a loss of USD 0.03 per share — a 70 percent jump in the deficit from a year earlier — on revenue of USD 231.6 million, an expected gain of 60.3 percent.
The Iridium Elephant
The defining strategic move remains the June announcement that Rocket Lab would acquire Iridium Communications for USD 8.0 billion, or USD 54 per share in cash and stock, with USD 5.5 billion of that structured as contingent consideration. Deutsche Bank and Wells Fargo have committed to a 364-day bridge facility of USD 3.6 billion. The deal is expected to close around mid-2027, pending Iridium shareholder approval and regulatory clearances. If completed, it would hand Rocket Lab L-band spectrum and a 60-satellite constellation — a decisive step away from pure launch services toward a vertically integrated space company.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The acquisitions of Mynaric AG, closed in April, and Motiv Space Systems, completed in May, may already be broadening the company's capabilities in the current quarter, analysts note.
Wall Street's Split Verdict
The analyst community is anything but unified on the stock. KGI Securities upgraded Rocket Lab from "Neutral" to "Outperform" on July 27 with a price target of USD 107.00. Piper Sandler's Alexander Potter initiated coverage with a Hold rating and an USD 83 target — implying upside of 17.8 percent but signaling caution. Clear Street's Gregory Pendy, by contrast, reaffirmed a Buy with a USD 129 target, citing expectations of faster growth through 2030 on rising launch demand and a swelling backlog.
Institutional positioning tells a similarly mixed story. Vanguard Capital Management has reported a 5.19 percent stake, representing more than 30 million shares. Meanwhile, the Equatorial Trust, attributed to CEO Peter Beck, sold roughly 3.3 million shares in early July at prices between USD 81 and USD 102 — executed under a pre-arranged trading plan, but still a notable insider exit.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Neutron's Shadow
The market's wariness is understandable. In January, a tank failure during testing pushed Neutron's first launch to late 2026. That delay matters more than usual now: the Space Force flatellite contract depends on a rocket that has never flown. The SpaceX IPO in June added another layer of competitive pressure, placing a deep-pocketed rival squarely in the launch and constellation arena.
The stock's 30-day annualized volatility sits at 83.24 percent — a figure more typical of biotech speculation than an established aerospace contractor. With second-quarter results due Monday after the US market close, the consensus projects a loss of USD 0.07 per share on revenue of USD 231.79 million. Whether investors focus on the contract momentum or the Neutron risk will likely determine if this rally has legs or fades into another episode in a volatile year. For now, Rocket Lab remains a high-beta bet on a story that keeps delivering — at a price that keeps testing investors' patience.
Ad
Rocket Lab Stock: New Analysis - 7 August
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
